[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ning Wang, MD., PhD.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":96},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,38,58,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100390842","a-registered-cohort-study-on-fshd1-100390842",false,"NCT04369209","A Registered Cohort Study on FSHD1","A Registered Observational Cohort Study of Facioscapulohumeral Muscular Dystrophy Type 1","Inclusion Criteria:\n\n* Male or female subjects of all ages at baseline\n* Subjects, with or without symptoms, with FSHD1 genetic confirmation through PFGE-based Southern blotting\n* Unrelated healthy controls\n\nExclusion Criteria:\n\n* Decline to participate\n* Other neuromuscular disease (such as Limb-girdle muscular dystrophy or Myotonic dystrophy)\n* Serious systemic illness (such as heart, liver, kidney disease or major mental illness)",true,"ALL",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","The data to be collected is intended to help healthcare providers make important medical and financial decisions concerning FSHD1, through an enhanced understanding of the prevalence, progression and natural history of FSHD1.",[24],"Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1)","RECRUITING","2024-08-23",{"date":28,"type":29},"2024-08-26","ACTUAL",{"date":31,"type":29},"2001-01",{"date":33,"type":20},"2031-12",{"name":35,"class":36},"Ning Wang, MD., PhD.","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":47,"conditions":48,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":37},"100363284","a-registered-cohort-study-on-cerebellar-ataxia-in-the-organization-in-south-east-china-for-cerebellar-ataxia-research-osccar-100363284","NCT04010214","A Registered Cohort Study on Cerebellar Ataxia in the Organization in South-East China for Cerebellar Ataxia Research (OSCCAR)","A Registered Cohort Study on Cerebellar Ataxia","Inclusion Criteria:\n\n* Patients with cerebellar ataxia based on the diagnoses of tow neurologists\n* Relatives of patients with cerebellar ataxia\n* Unrelated healthy controls\n* Participants or legal guardian(s) willing and able to complete the informed consent process\n\nExclusion Criteria:\n\n* Participants are unable to comply with trial procedures and visit schedule",{"count":46,"type":20},1500,"Cerebellar ataxia is a form of ataxia originating in the cerebellum. Cerebellar ataxia can occur as a result of many diseases and may present with symptoms of an inability to coordinate balance, gait, extremity and eye movements. To understand the clinical and genetic characteristics of cerebellar ataxia, we establish a registered cohort to follow up Chinese patients with cerebellar ataxia.",[49],"Cerebellar Ataxia","2023-07-11",{"date":52,"type":29},"2023-07-12",{"date":54,"type":29},"2019-07-01",{"date":56,"type":20},"2059-12",{"name":35,"class":36},{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":65,"targetDuration":67,"studyType":21,"phases":4,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":77,"locationsCount":37},"100363282","a-registered-cohort-study-on-charcot-marie-tooth-disease-100363282","NCT04010188","A Registered Cohort Study on Charcot-Marie-Tooth Disease","A Registered Observational Cohort Study of Charcot-Marie-Tooth Disease","Inclusion Criteria:\n\n* Patients with the clinical diagnosis of Charcot-Marie-Tooth disease\n* Genetic diagnosis of patients with Charcot-Marie-Tooth disease\n* Unrelated healthy controls\n\nExclusion Criteria:\n\n* Decline to participate.\n* Other peripheral neuropathy caused by trauma, immunity and toxicosis.",{"count":66,"type":20},500,"20 Years","The aim of the study is to analyze the natural history data data from Charcot-Marie-Tooth disease and related disorders in China, to assess the clinical, genetic, epigenetic features of patients with Charcot-Marie-Tooth disease, and to optimize clinical management.",[70],"Charcot-Marie-Tooth Disease","2022-01-07",{"date":73,"type":29},"2022-01-11",{"date":54,"type":29},{"date":76,"type":20},"2049-12-31",{"name":35,"class":36},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":95,"locationsCount":37},"100363473","a-registered-cohort-study-on-duchenne-muscular-dystrophy-100363473","NCT04012671","A Registered Cohort Study on Duchenne Muscular Dystrophy","Inclusion Criteria:\n\n* Beyond 2 years old\n* Diagnosis with Duchenne Muscular Dystrophy, and female carriers, genotypically confirmed\n* Diagnosis should be supported by muscle biopsy, if no genetic confirmation.\n\nExclusion Criteria:\n\n* Presence of other clinically significant illness","2 Years",{"count":86,"type":20},2000,"Dystrophinopathy is a term of X-linked recessive genetic disease, including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and the X-linked dilated cardiomyopathy. The aim of this study is to determine the clinical spectrum and natural progression of dystrophinopathy in a prospective multicenter natural history study, to assess the clinical, genetic of patients with dystrophinopathy to optimize clinical management.",[89],"Duchenne Muscular Dystrophy","2021-03-18",{"date":92,"type":29},"2021-03-22",{"date":54,"type":29},{"date":76,"type":20},{"name":35,"class":36},""]